Oxygen Biotherapeutics Inc.

EANS-Adhoc: Oxygen Biotherapeutics Receives Approval to Expand Phase IIb Trials with Oxycyte® PFC for Traumatic Brain Injury into India

  ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide
  distribution. The issuer is solely responsible for the content of this

Research & Development


MORRISVILLE, NC, June 7, 2011 - Oxygen Biotherapeutics, Inc. (NASDAQ & SIX Swiss Exchange: OXBT) today announced it has received approval to conduct its traumatic brain injury Phase IIb clinical trials known as STOP-TBI in India by the Drug Controller General of India. Oxygen Biotherapeutics believes the addition of India to its existing clinical sites in Switzerland and Israel will enable the Company to conclude the study faster and more economically. The next cohort is expected to begin in the second half of fiscal year 2012.

"We are pleased that we received this approval and look forward to working with our new clinical sites," said Chris Stern, Chairman and Chief Executive Officer of Oxygen Biotherapeutics. "Currently, we are amending the protocol to include patients with milder forms of TBI, and we are developing the processes for manufacturing cGMP Oxycyte PFC for the study. In addition, we are seeking a partner to help us execute the remaining aspects of this trial because we believe that makes strategic sense and is in the best interest of our shareholders."

The STOP-TBI study is a double-blind, placebo controlled dose-escalation study designed to evaluate the safety, efficacy and dosing parameters of Oxycyte PFC, a novel perfluorocarbon emulsion that is given intravenously to traumatic brain injury patients. The study´s first cohort has been completed and the database has been locked.

end of ad-hoc-announcement ========================================== ====================================== About Oxygen Biotherapeutics, Inc. Headquartered in Morrisville, NC, Oxygen Biotherapeutics, Inc. is developing medical and cosmetic products that efficiently deliver oxygen to tissues in the body. The company has developed a proprietary perfluorocarbon (PFC) therapeutic oxygen carrier that is being formulated for both intravenous and topical delivery. This year, the company launched its DERMACYTE® line of oxygen-rich skin care products. In addition, the company is focused on perfluorocarbon-based oxygen carriers for use in traumatic brain injury, decompression sickness, personal care, dermatology and topical wound healing. More information is available at www.oxybiomed.com or www.dermacyteus.com.

Caution Regarding Forward-Looking Statements This news release contains certain forward-looking statements by the company that involve risks and uncertainties and reflect the company's judgment as of the date of this release. These statements include the management transition, and expansion of research and development of the Oxycyte product line, including and the timing of the introduction of those new products. The forward-looking statements are subject to a number of risks and uncertainties including matters beyond the company’s control that could lead to delays in new product introductions and customer acceptance of these new products, and other risks and uncertainties as described in our filings with the Securities and Exchange Commission, including in the current report on Form 10-Q filed on September 9, 2010. The company disclaims any intent or obligation to update these forward-looking statements beyond the date of this release. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

end of announcement                               euro adhoc
issuer:      Oxygen Biotherapeutics Inc.
          2530 Meridian Pkwy
          US-27713 Durham, NC
phone:       +1(919)7607606
FAX:         +1(419)7108764
mail:     c.stern@oxybiomed.com
WWW:      www.oxybiomed.com
sector:      Biotechnology
ISIN:        US69207P2092
indexes:     SSIRT
stockmarkets: Nasdaq: New York, Main Standard: SIX Swiss Exchange
language: English 


Ellen Corliss
Vice President, Corporate Communications
& Investor Relations
Oxygen Biotherapeutics, Inc
One Copley Parkway, Suite 490
Morrisville, NC 27560
Direct Telephone: +1 919 855 2112
Direct Fax: +1 919 806 4417
Email: e.corliss@oxybiomed.com

Branche: Biotechnology
ISIN: US69207P2092
WKN: 10728277
Index: SSIRT
Börsen: New York / Nasdaq
SIX Swiss Exchange / Main Standard

Weitere Meldungen: Oxygen Biotherapeutics Inc.

Das könnte Sie auch interessieren: